SAMAD SAM 4

What Happened
Sam Samad, Executive Vice President & Chief Financial Officer of Quest Diagnostics (DGX), was granted 102 restricted share units (RSUs) on July 22, 2026. The grant is reported at an equivalent value of $206.81 per share, totaling approximately $21,094. This was a compensation award (not an open‑market purchase or sale).

Key Details

• Transaction date: 2026-07-22; reported on Form 4 filed 2026-07-27 (appears to be filed after the typical 2-business-day window).
• Award type and amount: 102 restricted share units (RSUs) at $206.81 each; total ~$21,094.
• Shares owned after transaction: Not disclosed in this Form 4.
• Footnotes: F1 = award of restricted share units. F2 = references shares from a dividend reinvestment plan that the reporting person chose to report early on Form 4 (eligible for deferred Form 5 reporting under Rule 16a-6).
• Transaction code: A = Award/Grant.

Context
RSU grants are a common form of executive compensation and do not represent an open‑market buy or sell (they are not an immediate market sentiment signal). The filing lists the grant value and notes a dividend reinvestment item reported early; no option exercises, sales, or gifts are involved in this entry.